New proton beam machine shows promise in tumor control trial
NCT ID NCT06347731
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new proton therapy device, the Varian ProBeam360°, in 47 people with solid tumors. The goal was to see if it could control tumor growth with few severe side effects. Participants received radiation for 1 to 8 weeks and were followed for up to 5 years. The main measure was disease control rate at 3 months, with a target of 80%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Proton radiation therapy (Varian ProBeam360° system)
What this could lead to
If successful, this could provide a more precise and safer radiation option for treating solid tumors, potentially reducing damage to healthy tissue.
What could go wrong
This is a small, single-center trial without a comparison group. The results may not apply to all patients or tumor types. Proton therapy is not new, so the main question is whether this specific device performs as well as existing systems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China